Premium
Immature reticulocytes are sensitive and specific to low‐dose erythropoietin treatment at sea level and altitude
Author(s) -
Jeppesen Jan Sommer,
Breenfeldt Andersen Andreas,
Bonne Thomas Christian,
Thomassen Martin,
Sørensen Helle,
Nordsborg Nikolai Baastrup,
Olsen Niels Vidiendal,
Huertas Jesús Rodríguez,
Bejder Jacob
Publication year - 2021
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.3031
Subject(s) - reticulocyte , flow cytometry , erythropoietin , medicine , andrology , red blood cell , placebo , chemistry , gastroenterology , microbiology and biotechnology , immunology , biology , pathology , biochemistry , messenger rna , gene , alternative medicine
We investigated whether immature reticulocyte fraction (IRF) and immature reticulocytes to red blood cells ratio (IR/RBC) are sensitive biomarkers for low‐dose recombinant human erythropoietin (rhEpo) treatment at sea level (SL) and moderate altitude (AL) and whether multi (FACS) or single (Sysmex‐XN) fluorescence flow cytometry is superior for IRF and IR/RBC determination. Thirty‐nine participants completed two interventions, each containing a 4‐week baseline, a 4‐week SL or AL (2,230 m) exposure, and a 4‐week follow‐up. During exposure, rhEpo (20 IU kg −1 ) or placebo (PLA) was injected at SL (SL rhEpo , n = 25, SL PLA n = 9) and AL (AL rhEpo , n = 12, AL PLA n = 27) every second day for 3 weeks. Venous blood was collected weekly. Sysmex measurements revealed that IRF and IR/RBC were up to ~70% ( P < 0.01) and ~190% ( P < 0.001) higher in SL rhEpo than SL PLA during treatment and up to ~45% ( P < 0.001) and ~55% ( P < 0.01) lower post‐treatment, respectively. Compared with AL PLA , IRF and IR/RBC were up to ~20% ( P < 0.05) and ~45% ( P < 0.001) lower post‐treatment in SL rhEpo , respectively. In AL rhEpo , IRF and IR/RBC were up to ~40% ( P < 0.05) and ~110% ( P < 0.001) higher during treatment and up to ~25% ( P < 0.05) and ~40% ( P < 0.05) lower post‐treatment, respectively, compared with AL PLA . Calculated thresholds provided ~90% sensitivity for both biomarkers at SL and 33% (IRF) and 66% (IR/RBC) at AL. Specificity was >99%. Single‐fluorescence flow cytometry coefficient of variation was >twofold higher at baseline ( P < 0.001) and provided larger or similar changes compared to multi‐fluorescence, albeit with smaller precision. In conclusion, IRF and IR/RBC were sensitive and specific biomarkers for low‐dose rhEpo misuse at SL and AL.